Use of Human Immunodeficiency Virus-1 Protease Inhibitors Is Associated With Atherogenic Lipoprotein Changes and Endothelial Dysfunction

Background—Human immunodeficiency virus protease inhibitors (HIV PIs) are associated with hyperlipidemia, hyperglycemia, and obesity; however, it is not known whether they increase risk of atherosclerotic vascular disease. The purposes of this study were to characterize the lipoprotein abnormalities associated with use of HIV PIs in individuals with HIV infection and to determine the pathophysiological significance of these changes by assessing their effect on endothelial dysfunction. Methods and Results—This was a cross-sectional study of 37 adults with HIV-1 infection who were receiving antiretroviral therapy. Twenty-two were taking HIV PIs (group 1); 15 were not (group 2). Lipids and lipoproteins were measured by enzymatic techniques and nuclear magnetic resonance spectroscopic analysis. Flow-mediated vasodilation (FMD) of the brachial artery was measured by high-resolution ultrasound. Subjects in both groups were similar in regard to age, time since diagnosis of HIV infection, and CD4 cell count. Group 1 subjects had higher total cholesterol (5.68 versus 4.42 mmol/L, P =0.007) and triglyceride (4.43 versus 1.98 mmol/L, P =0.009) levels, characterized by elevated levels of IDL and VLDL. Subjects in group 1 had impaired FMD (2.6±4.6%), indicative of significant endothelial dysfunction. Group 2 subjects had normal FMD (8.1±6.7%, P =0.005). In group 1, chylomicron, VLDL, IDL, and HDL cholesterol levels predicted FMD. Conclusions—Use of HIV PIs is associated with atherogenic lipoprotein changes and endothelial dysfunction. Because these metabolic and vascular changes predispose to atherosclerosis, monitoring and treatment of dyslipidemia in patients taking these medications is warranted.

[1]  J. Otvos,et al.  Measurement of lipoprotein subclass profiles by nuclear magnetic resonance spectroscopy. , 2002, Clinical laboratory.

[2]  Nader Rifai,et al.  Handbook of Lipoprotein Testing , 2001 .

[3]  J. Weiel,et al.  HIV Protease Inhibitors Stimulate Hepatic Triglyceride Synthesis , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[4]  S. Hammer,et al.  Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study. , 2000, Archives of internal medicine.

[5]  K. Kostner,et al.  Late prognostic value of flow-mediated dilation in the brachial artery of patients with chest pain. , 2000, The American journal of cardiology.

[6]  A M Zeiher,et al.  Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. , 2000, Circulation.

[7]  S. Jacob,et al.  Endothelial dysfunction is detectable in young normotensive first-degree relatives of subjects with type 2 diabetes in association with insulin resistance. , 2000, Circulation.

[8]  S. Higano,et al.  Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. , 2000, Circulation.

[9]  J. Leonard,et al.  Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects , 2000, AIDS.

[10]  M. Schambelan,et al.  Hyperlipidemia and Insulin Resistance Are Induced by Protease Inhibitors Independent of Changes in Body Composition in Patients With HIV Infection , 2000, Journal of acquired immune deficiency syndromes.

[11]  Ames,et al.  PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA , 2000 .

[12]  J. Stein,et al.  Purple grape juice improves endothelial function and reduces the susceptibility of LDL cholesterol to oxidation in patients with coronary artery disease. , 1999, Circulation.

[13]  S M Marcovina,et al.  Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. , 1999, Circulation.

[14]  D. Cooper,et al.  Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: acohort study , 1999, The Lancet.

[15]  F. Ohsuzu,et al.  Endothelium-dependent flow-mediated vasodilation in coronary and brachial arteries in suspected coronary artery disease. , 1998, The American journal of cardiology.

[16]  D. Freedman,et al.  Relation of lipoprotein subclasses as measured by proton nuclear magnetic resonance spectroscopy to coronary artery disease. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[17]  K. Kugiyama,et al.  Association of remnant lipoprotein levels with impairment of endothelium-dependent vasomotor function in human coronary arteries. , 1998, Circulation.

[18]  D. Vittecoq,et al.  Vascular complications associated with use of HIV protease inhibitors , 1998, The Lancet.

[19]  David A. Cooper,et al.  A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors , 1998, AIDS.

[20]  K. Henry,et al.  Severe premature coronary artery disease with protease inhibitors , 1998, The Lancet.

[21]  John Ludbrook,et al.  Why Permutation Tests are Superior to t and F Tests in Biomedical Research , 1998 .

[22]  K. Miller,et al.  Visceral abdominal-fat accumulation associated with use of indinavir , 1998, The Lancet.

[23]  K. Schenck-Gustafsson,et al.  Transient triglyceridemia decreases vascular reactivity in young, healthy men without risk factors for coronary heart disease. , 1997, Circulation.

[24]  K. Feingold,et al.  Abnormalities of apolipoprotein E in the acquired immunodeficiency syndrome. , 1997, The Journal of clinical endocrinology and metabolism.

[25]  G. Dagenais,et al.  Associations of HDL2 and HDL3 subfractions with ischemic heart disease in men. Prospective results from the Québec Cardiovascular Study. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[26]  D. Green,et al.  Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. , 1997, Circulation.

[27]  D. Spiegelhalter,et al.  Non-invasive measurement of human endothelium dependent arterial responses: accuracy and reproducibility. , 1995, British heart journal.

[28]  A. Yeung,et al.  The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. , 1995, The New England journal of medicine.

[29]  R. Krauss,et al.  The hypertriglyceridemia of acquired immunodeficiency syndrome is associated with an increased prevalence of low density lipoprotein subclass pattern B. , 1993, The Journal of clinical endocrinology and metabolism.

[30]  J. K. Lloyd,et al.  Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis , 1992, The Lancet.

[31]  K. Feingold,et al.  Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. , 1992, The Journal of clinical endocrinology and metabolism.